Skip Nav Destination

First Edition

Research Article May 23 2024

Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis

Michael L Wang,Tadeusz Robak, Prof.,Kami J Maddocks,Tycel J. Phillips,Stephen Douglas Smith,David Gallinson,Roser Calvo, MD PhD,Chuan-Chuan Wun,Veerendra Munugalavadla,Wojciech Jurczak

View article

Supplementary data

Research Article May 22 2024

Racial, Ethnic and Socioeconomic Diversity and Outcomes of Patients with Graft-versus-Host Disease: A CIBMTR Analysis

View article

Supplementary data

Letter May 22 2024

Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myeloma

Heinz Ludwig,Nikhil C. Munshi,Evangelos Terpos,Ilvy Schweitzer,Noopur Raje,Philippe Moreau,Ajay K. Nooka

View article

Supplementary data

Research Article May 20 2024

Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma

View article

Supplementary data

Research Article May 17 2024

Metformin use and risk of myeloproliferative neoplasms - a Danish population-based case-control study

Daniel Tuyet Kristensen,Andreas Kiesbye Øvlisen,Lasse Hjort Jakobsen,Marianne Tang Severinsen,Louise Hur Hannig,Jørn Starklint,Morten Hagemann Hilsøe,Anders Pommer Vallentin,Mette Brabrand,Hans Carl Hasselbalch,Tarec Christoffer El Galaly,Anne Stidsholt Roug

View article

Supplementary data

Research Article May 15 2024

Active infection at the time of CD34+ selected stem cell boost is associated with treatment failure and poor survival

View article

Supplementary data

Research Article May 13 2024

A JAGN1-associated severe congenital neutropenia zebrafish model revealed an altered G-CSFR signaling and UPR activation

Larissa Doll,Karl Welte,Julia Skokowa,Baubak Bajoghli

View article

Supplementary data

Review Article May 8 2024

Need for consensus on primary endpoints and efficacy definitions in trials for adult acute lymphoblastic leukemia

Matthew J Wieduwilt

View article

Research Article May 7 2024

Neoantigen Landscape Supports Feasibility of Personalized Cancer Vaccine for Follicular Lymphoma

View article

Supplementary data

Research Article April 30 2024

Long-term Outcomes of Peripheral Blood Stem Cell Unrelated Donors Mobilized with Filgrastim

Heather E Stefanski,Michelle Kuxhausen,Stephanie Bo-Subait,Hati Kobusingye,Deborah Mattila,Jennifer Schenfeld,Darcie Sandschafer,Linda J. Burns,Bronwen E. Shaw,Michael A Pulsipher,John P. Miller,Steven M. Devine

View article

Supplementary data

Research Article April 26 2024

High-dose Alemtuzumab-Cyclosporine vs Tacrolimus-Methotrexate-Sirolimus for Chronic Graft-versus-Host Disease Prevention

Noa G. Holtzman,Lauren M Curtis,Rachel B Salit,Brian C Shaffer,Filip Pirsl,Alen Ostojic,Seth M Steinberg,Eduard Schulz,Jennifer S. Wilder,Thomas E Hughes,Jeremy Rose,Sarfraz Memon,Robert Korngold,Juan Gea-Banacloche,Daniel H Fowler,Frances T Hakim,Ronald E. Gress,Michael R. Bishop,Steven Z Pavletic

View article

Supplementary data

Research Article April 26 2024

Myosin-1C augments secretion of von Willebrand factor by linking contractile actomyosin machinery to the plasma membrane

Sammy El-Mansi,Tom P Mitchell, Dr,Golzar Mobyen,Thomas AJ McKinnon,Pika Miklavc,Manfred Frick,Thomas D Nightingale

View article

Supplementary data

Research Article April 26 2024

Venous Thromboembolism Characteristics and Outcomes Among RIETE Patients Tested & Untested for Inherited Thrombophilia

Omri Cohen,Liat Waldman Radinsky,Gili Kenet,Isabelle Mahe,Giovanni Barillari,Silvia Soler,Patricia Sigüenza,Maria del Valle Morales,Paula Villares,Manuel Monreal

View article

Research Article April 25 2024

Maternal red blood cell alloimmunization prevalence in the United States

Ronan P Sugrue,Kenneth J Moise, Jr,Jerome J Federspiel,Elizabeth Abels,Judy Z Louie,Zhen Chen,Lance A. Bare,Damian P Alagia, III,Harvey W Kaufman

View article

Supplementary data

Research Article April 19 2024

Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease

Santosh L Saraf,Robert Ward Hagar,Modupe Idowu,Ifeyinwa Osunkwo,Kimberly Cruz,Frans A Kuypers,R. Clark Brown,James Geib,Maria D Ribadeneira,Patricia Schroeder,Eric Wu,Sanjeev Forsyth,Patrick F. Kelly,Theodosia A. Kalfa,Marilyn J. Telen

View article

Supplementary data

Research Article April 19 2024

Final phase I substudy results of ivosidenib in patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome

Courtney D. D DiNardo,Gail J. Roboz,Justin M Watts,Yazan F Madanat,Gabrielle T. Prince,Praneeth Baratam,Stéphane de Botton,Anthony S. Stein,James M Foran,Martha L. Arellano,David A Sallman,Mohammad Hossain,Dylan M. Marchione,Xiaofei Bai,Prapti A. Patel,Stephanie M. Kapsalis,Guillermo Garcia-Manero,Amir T. Fathi

View article

Supplementary data

Research Article April 19 2024

Rates of severe neutropenia and infection risk in patients treated with deferiprone: 28 years of data

Sherif M. Badawy,Jan Palmblad,Fernando Tricta,Noemi Toiber Temin,Caroline Fradette,Leo Lin,Anna Rozova,Sujit Sheth

View article

Research Article April 10 2024

Haploidentical transplantation in primary refractory/relapsed secondary versus de novo AML: from the ALWP/EBMT

Arnon Nagler,Myriam Labopin,Johanna Tischer,Anna Maria Raiola,Desiree Kunadt,Jan Vydra,Didier Blaise,Patrizia Chiusolo,Renato Fanin,Julia Winkler,Edouard Forcade,Gwendolyn van Gorkom,Fabio Ciceri,Mohamad Mohty

View article

Supplementary data

Research Article April 9 2024

Final Outcomes from a Phase 2 Trial of Posoleucel in Allogeneic Hematopoietic Cell Transplant Recipients

Sanjeet Singh Dadwal,Rajat Bansal,Michael Schuster,Jean A. Yared,Gary Douglas Myers,Michelle Elizabeth Matzko,Sama Adnan,David McNeel,Julie Ma,Sarah A Gilmore,Spyridoula Vasileiou,Ann M Leen,Joshua A Hill,Jo-Anne Young

View article

Supplementary data

Letter March 27 2024

Ancestral β-globin gene haplotypes modify β-thalassemia severity in a mouse model

Christophe Lechauve,Julia Keith,Alfonso G. Fernandez,Eugene Khandros,Kalin Mayberry,Thiyagaraj Mayuranathan,Lance E Palmer,Xiaohui Qiu,Heather Sheppard,Rahul Telange,Hans-Martin Herz,Mitchell J. Weiss

View article

Supplementary data

Research Article March 1 2024

It is feasible and safe to stop specialized follow-up of asymptomatic lower risk chronic lymphocytic leukemia

Christian Brieghel,Caspar da Cunha-Bang,Jindrich Mourek,Lars Kjeldsen,Carsten Utoft Niemann

View article

Supplementary data

Page 3 of 3

First Edition

Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis

Racial, Ethnic and Socioeconomic Diversity and Outcomes of Patients with Graft-versus-Host Disease: A CIBMTR Analysis

Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myeloma

Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma

Metformin use and risk of myeloproliferative neoplasms - a Danish population-based case-control study

Active infection at the time of CD34+ selected stem cell boost is associated with treatment failure and poor survival

A JAGN1-associated severe congenital neutropenia zebrafish model revealed an altered G-CSFR signaling and UPR activation

Need for consensus on primary endpoints and efficacy definitions in trials for adult acute lymphoblastic leukemia

Neoantigen Landscape Supports Feasibility of Personalized Cancer Vaccine for Follicular Lymphoma

Long-term Outcomes of Peripheral Blood Stem Cell Unrelated Donors Mobilized with Filgrastim

High-dose Alemtuzumab-Cyclosporine vs Tacrolimus-Methotrexate-Sirolimus for Chronic Graft-versus-Host Disease Prevention

Myosin-1C augments secretion of von Willebrand factor by linking contractile actomyosin machinery to the plasma membrane

Venous Thromboembolism Characteristics and Outcomes Among RIETE Patients Tested & Untested for Inherited Thrombophilia

Maternal red blood cell alloimmunization prevalence in the United States

Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease

Final phase I substudy results of ivosidenib in patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome

Rates of severe neutropenia and infection risk in patients treated with deferiprone: 28 years of data

Haploidentical transplantation in primary refractory/relapsed secondary versus de novo AML: from the ALWP/EBMT

Final Outcomes from a Phase 2 Trial of Posoleucel in Allogeneic Hematopoietic Cell Transplant Recipients

Ancestral β-globin gene haplotypes modify β-thalassemia severity in a mouse model

It is feasible and safe to stop specialized follow-up of asymptomatic lower risk chronic lymphocytic leukemia

ASH Publications

American Society of Hematology

First Edition

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only